Boost for GSK
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
Nine months out from landing $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has ...
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
The multi-programme partnership will also see Relation applying its platform to a range of fibrotic conditions as well as ...
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the ...
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.
Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it is involved in 15 clinical trials, of which 12 were completed, and 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback